Haemonetics (NYSE:HAE)‘s stock had its “buy” rating reaffirmed by Jefferies Financial Group in a research report issued to clients and investors on Tuesday, August 7th, The Fly reports. They presently have a $125.00 price target on the medical instruments supplier’s stock. Jefferies Financial Group’s target price would indicate a potential upside of 11.97% from the company’s previous close. Jefferies Financial Group also issued estimates for Haemonetics’ Q2 2019 earnings at $0.54 EPS, Q3 2019 earnings at $0.59 EPS, Q4 2019 earnings at $0.56 EPS, FY2019 earnings at $2.28 EPS, FY2020 earnings at $3.30 EPS, FY2021 earnings at $4.25 EPS and FY2022 earnings at $4.95 EPS.
Several other equities research analysts have also recently weighed in on HAE. ValuEngine raised shares of Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 9th. Zacks Investment Research cut shares of Haemonetics from a “strong-buy” rating to a “sell” rating in a research report on Wednesday, April 11th. Morgan Stanley increased their target price on shares of Haemonetics from $77.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, May 9th. Barrington Research increased their target price on shares of Haemonetics to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, May 9th. Finally, TheStreet raised shares of Haemonetics from a “c+” rating to a “b” rating in a research report on Tuesday, May 8th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Haemonetics currently has an average rating of “Buy” and a consensus target price of $98.33.
NYSE:HAE traded up $2.24 during mid-day trading on Tuesday, hitting $111.64. 424,800 shares of the stock traded hands, compared to its average volume of 589,950. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of 58.50, a PEG ratio of 4.49 and a beta of 0.99. The company has a current ratio of 2.84, a quick ratio of 1.94 and a debt-to-equity ratio of 0.49. Haemonetics has a 52 week low of $41.26 and a 52 week high of $111.79.
In related news, CFO William P. Mr. Burke sold 6,687 shares of the stock in a transaction on Monday, June 25th. The shares were sold at an average price of $92.17, for a total transaction of $616,340.79. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher Simon sold 5,139 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $89.31, for a total transaction of $458,964.09. The disclosure for this sale can be found here. Insiders sold 23,711 shares of company stock worth $1,926,700 in the last quarter. Company insiders own 1.04% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Wagner Bowman Management Corp purchased a new position in Haemonetics in the second quarter worth approximately $224,000. Arjuna Capital purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $224,000. Granahan Investment Management Inc. MA purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $229,000. Alpine Woods Capital Investors LLC purchased a new stake in shares of Haemonetics during the 1st quarter worth approximately $236,000. Finally, Zeke Capital Advisors LLC purchased a new stake in shares of Haemonetics during the 2nd quarter worth approximately $244,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Story: Fundamental Analysis and Individual Investors
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.